Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. - Wikidata - awgldk - TriplyDB

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

http://www.wikidata.org/entity/Q33212010

about

APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism--individual patient variability in disease presentation, course and response to therapy Glomerular diseases: FSGS.Targeted exome sequencing integrated with clinicopathological information reveals novel and rare mutations in atypical, suspected and unknown cases of Alport syndrome or proteinuria The impact of sex in primary glomerulonephritis.Angiotensin-converting enzyme gene polymophism in adult primary focal segmental glomerulosclerosis.Moxibustion Alleviates Injury in a Rat Focal Segmental Glomerulosclerosis Model.Proteomic profiling identifies haptoglobin as a potential serum biomarker for steroid-resistant nephrotic syndrome.Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome.Clinical features and outcomes of IgA nephropathy with nephrotic syndrome.MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists.Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1.Therapeutic approach to FSGS in children.A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Clinical trial of focal segmental glomerulosclerosis in children and young adults.Targeted next-generation sequencing in steroid-resistant nephrotic syndrome: mutations in multiple glomerular genes may influence disease severity Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS.The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome.Circulating suPAR in two cohorts of primary FSGS.Complete Remission in the Nephrotic Syndrome Study Network.Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS.Value of a complete or partial remission in severe lupus nephritis.Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation Effects of Therapy on Urine Neutrophil Gelatinase-Associated Lipocalin in Nondiabetic Glomerular Diseases with Proteinuria.Experience with tacrolimus in children with steroid-resistant nephrotic syndrome.Clinicopathological correlation and treatment response of primary focal segmental glomerulosclerosis in adults and adolescents.Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction.Novel biomarkers in glomerular disease.Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.

P2860

Q24631837-DF68F12C-E19F-4C88-964F-48354CE138E4 Q26752836-6995E378-4D96-40F8-ADB6-3D7C3FD42346 Q27015909-18149F3A-AED2-404D-A856-EEFC6872933F Q27687257-FE352DE8-7B1E-43FB-9AD0-6560AB2A38AD Q28534316-CB2B8E97-A0EC-44FE-A347-5CE509314D3D Q33313682-5553C795-B756-4358-B09B-50A1CC032898 Q33688313-77096B2B-054F-4340-90F9-3C3DF3C8E814 Q33786923-94DF86E4-B329-4182-8194-2B487B404F76 Q34324615-B4B56262-35A8-4CA4-8EC6-77390AC73004 Q34455143-7F5D16CA-2EAF-4D0B-9E76-98FA2A7D626D Q34556394-77C9ECDA-9277-48B4-97FE-926F070079D3 Q34639646-A0D467CE-428A-4D6C-AEAB-8AFD50929D74 Q34660643-9D85B25F-0B97-43B8-B909-7EAA9C78CC36 Q34990741-3B4C337A-D036-4339-8D9B-1EB067E3997F Q35028015-1FBE96FD-D213-4FF3-A7C7-82EABEB7A287 Q35310613-B5C8DE91-580C-48FF-860E-952882233D7C Q35576147-FF7EC48C-F510-4BB8-B87C-28C1D1BBC7C1 Q35614311-D87B88CA-DA3E-4DDE-AEFB-ED85697EDEA8 Q35669295-DAC36773-BC33-4A0D-9FA7-9D2CD8E0D339 Q35704498-0D6D5DC6-B244-4189-AB99-3962839104AD Q35837532-16212820-CC40-4470-89F8-15974702C978 Q35959709-AEF97838-DC3E-4C0C-8E10-7A100B6371BA Q35976834-9845B4CF-5901-48D5-89BA-8AEE31A61C69 Q36003095-EA7E5BC6-4780-4AB9-867D-4B1738663604 Q36098017-5AAA21CD-3CC8-4049-8A91-5858F1F6AA85 Q36426091-C7E573E9-EA15-437F-9D0E-2395B5319A6B Q36432859-015217E6-47BD-48D6-8F77-FCDFF41C61BF Q36543103-1A2B9BB9-AD45-4F15-B3E7-58F23A1A67F5 Q36583388-86806216-A5E2-46B3-9B12-0D12F38C810E Q36666936-E68847DC-A6AE-49FE-9AA4-05860F172D1D Q36686985-5319CDC1-20E5-4572-8DED-6B61A23E9D03 Q36717656-444F6622-AD06-45A7-961D-BCE69CABFB7E Q36987307-E4EF0BEA-1C2E-4EE4-A777-4D4FD4498D25 Q37157018-0E5252E8-3AC8-4A50-AE2D-1089A01E417F Q37229944-F437E5A8-54EC-44DC-BC63-8E300A8AE5E8 Q37241092-4DE61CEB-17FD-4A16-9959-998FCD964EB9 Q37359035-68E2E141-E7FF-45FD-8202-0F3184CFB305 Q37434558-A0BC3ED1-29F8-4805-9F9D-75AEB3B7DE4A Q37658483-411911C4-0B67-4CCB-BDC9-B6559CBA0D2D Q37928188-14BEE071-987D-4F31-884A-A98D3F2A84AD

P2860

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

http://www.wikidata.org/entity/Q33212010

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@ast

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@en

type

label

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@ast

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@en

prefLabel

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@ast

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@en

P1433

Q33212010-9FCCF76D-1A5D-42C5-9F67-BBFE38556FBB

P1476

Q33212010-AB25A605-C9A3-46F5-A841-B6FC83F249D0

P2093

Q33212010-29A04AE0-C520-4198-9DEF-0DBA96A1F1FE

Q33212010-651D6548-06DF-4D51-B672-4DEBF5AE8087

Q33212010-927A08FF-28AD-430E-8BFD-6FBC38C411D5

Q33212010-D6EAB37D-F220-4130-B991-1D47B4ABC7AC

Q33212010-F34210F2-51DB-4B4F-9883-2C3194AD203A

Q33212010-F43320C4-B16B-4BB3-AD10-2E8683FE403B

P304

Q33212010-D8A55AA5-7027-44E6-8E00-B29C7B711968

P31

Q33212010-11E2608A-FEB1-48A8-BA0E-CB5AB3ECD9CF

P356

Q33212010-C645672D-B8C3-49A7-B516-14C558DAC665

P433

Q33212010-A630564C-44E2-44B7-B5F7-1683889BE592

P478

Q33212010-BB0CEA90-1EB7-4A21-926A-C9AB3FE3A867

P577

Q33212010-6D7DD120-82DE-467D-AECD-59B1F2A33939

P698

Q33212010-E4D65660-CB49-477A-A964-655AA8386470

P356

P1433

Journal of the American Society of Nephrology

P1476

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

@en

P2093

Catherine A Wall

http://www.w3.org/2001/XMLSchema#string

Daniel C Cattran

http://www.w3.org/2001/XMLSchema#string

James W Scholey

http://www.w3.org/2001/XMLSchema#string

Judith A Miller

http://www.w3.org/2001/XMLSchema#string

Stéphan Troyanov

http://www.w3.org/2001/XMLSchema#string

Toronto Glomerulonephritis Registry Group

http://www.w3.org/2001/XMLSchema#string

P304

1061-1068

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2004070593

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15716334

http://www.w3.org/2001/XMLSchema#string